What's breaking now, across thousands of outlets.
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
IonQ has "multiple ways to win" but investors are paying for growth that is not yet realized.
IonQ has "multiple ways to win" but investors are paying for growth that is not yet realized.
The rate of payments-related revenue growth in North America, and globally, will slow in the next four years, a major consulting firm predicts.
AMD has multiple catalysts that could catapult it into the $3 trillion market cap club by the end of the decade.